PROTON PUMP INHIBITORS BETWEEN BENEFITS AND RISKS

The possible risks of proton pump inhibitors.

5 roton pump inhibitors (PPIs) suppress gastric acid secretion by selectively inhibiting the enzyme P hydrogenepotassium adenosine triphosphatase, located in gastric parietal cells. These drugs superseded H2-receptor antagonists as first-line acid suppressants in the 1980s, and their potent effect has revolutionised the management of common upper gastrointestinal (GI) disorders, including gastr...

Interaction between clopidogrel and proton pump inhibitors.

The drug interaction between proton pump inhibitors and clopidogrel has been the subject of much study in recent years. Contradictory results regarding the effect of proton pump inhibitors on platelet reactivity and on clinical outcome in clopidogrel-treated patients have been reported in literature. Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopi...

Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits

Nonsteroidal anti-inflammatory drugs (NSAIDs) are often coadministered with proton-pump inhibitors (PPIs) to reduce NSAID-induced gastrointestinal (GI) adverse events. This coadministration is generally regarded as safe, and is included in many of the guidelines on NSAID prescription. However, recent evidence indicates that the GI risks associated with NSAIDs can be potentiated when they are co...

Proton pump inhibitors: Risks of long-term use.

Proton pump inhibitors are among the most commonly prescribed classes of drugs, and their use is increasing, in particular for long-term treatment, often being over-prescribed and used for inappropriate conditions. In recent years, considerable attention has been directed towards a wide range of adverse effects, and even when a potential underlying biological mechanism is plausible, the clinica...

Proton Pump Inhibitors: Omeprazole